Kappa opioid receptor antagonists

Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514279, C07D48906, A61K 3144

Patent

active

054572088

ABSTRACT:
Compounds of the formula: ##STR1## are provided, which are selective kappa opioid receptor antagonists, wherein R.sup.1 is (C.sub.1 -C.sub.5)alkyl, C.sub.3 -C.sub.6 (cycloalkyl)alkyl, C.sub.5 -C.sub.7 (cycloalkenyl)alkyl, (C.sub.6 -C.sub.12)aryl, (C.sub.6 -C.sub.12)aralkyl, trans (C.sub.4 -C.sub.5) alkenyl, allyl or furan-2-ylalkyl; R.sup.2 is H, OH or O.sub.2 C(C.sub.1 -C.sub.5)alkyl; R.sup.3 is H, (C.sub.6 -C.sub.10)aralkyl, (C.sub.1 -C.sub.5)alkyl or (C.sub.1 -C.sub.5)alkylCO; X is O, S or NY, wherein Y is H or (C.sub.1 -C.sub.5)alkyl; R.sup.4 is CH.sub.2 (methylene) or C.dbd.O (carbonyl), R.sup.5 is CH.sub.2, C.dbd.O or C.dbd.NH (imino) and R.sup.6 is (C.sub.1 -C.sub.4)alkyl or NH(C.sub.1 -C.sub.4)alkyl, optionally substituted by a non-terminal (C.sub.1 -C.sub.2)alkyl group or by N(R.sup.7) (R.sup.8) wherein R.sup.7 and R.sup.8 are individually H or (C.sub.1 -C.sub.3) alkyl, with the proviso that one of R.sup.4 or R.sup.5 is CH.sub.2, and the pharmaceutically acceptable salts thereof.

REFERENCES:
patent: 4362870 (1982-07-01), Portoghese
patent: 4401672 (1983-08-01), Portoghese
patent: 4649200 (1987-03-01), Portoghese et al.
patent: 4730848 (1988-03-01), Portoghese
patent: 4806556 (1989-02-01), Portoghese
patent: 4816586 (1989-03-01), Portoghese
patent: 5223507 (1993-06-01), Dappen et al.
patent: 5225417 (1993-07-01), Dappen et al.
patent: 5352680 (1994-10-01), Portoghese et al.
patent: 5354863 (1994-10-01), Dappen
Department of Health, Education and Welfare, Public Health Service, Grant Application Nos. DA 1533-01 (Jun. 23, 1976); May 11, 1977 (02); May 10, 1978 (03); May 30, 1979 (04); Jul. 17, 1980 (05); May 26, 1981 (06); Jun. 2, 1982 (07); Jun. 13, 1983 (08); May 10, 1984 (09); May 31, 1985 (10); Jun. 9, 1986 (11); (not dated) (12); (not dated) (13); Not complete (pp 31-34 omitted) (14); May 31, 1990 (15); May 29, 1991 (16); and Mar. 26, 1992 (17).
J. C. Froehlich et al., "Naloxon Attenuates Voluntary Ethanol Intake in Rats Selectively Bred for High Ethanol Preference", Pharm. Biochem. Behav., 35, 385 (1990).
J. C. Froehlich et al., "Importance of Delta Opioid Receptors in Maintaining High Alcohol Drinking", Psychopharmacol., 103, 467 (1991).
M. Gates et al., "Some Potent Morphine Antagonists Possessing High Analgesic Activity", J. Med. Chem., 7, 127 (1964).
G. Henderson et al., "A New Example of a Morphine-Sensitive Neuro-Effector Junction: Adrenergic Transmission in the Mouse Vas Deferens", Brit. J. Pharmacol., 46, 764-766 (1972).
W. R. Martin, "Pharmacology of Opioids", Pharmacol. Rev., 35, 283-323 (1983).
S. L. Olmsted et al., "A Remarkable Change of Opioid Receptor Selectivity on the Attachment of a Peptidomimetic kappa Address Element to the delta Antagonist, Natrindole", J. Med. Chem., 36, 179-180 (1993).
P. S. Portoghese et al., "Application of the Message Address Concept in the Design of Highly Potent and Selective Non-Peptide delta Opioid Receptor Antagonists", J. Med. Chem., 31, 281 (1988).
P. S. Portoghese et al., "Only One Pharmacophore is Required for the kappa Opioid Antagonist Selectivity of Norbinaltorphimine", J. Med. Chem., 31, 1344 (1988).
P. S. Portoghese et al., "Bivalent Ligands and the Message-Address Concept in the Design of Selective Opioid Receptor Antagonists", Trends Pharmacol. Sci., 10, 230 (1989).
P. S. Portoghese et al., "Design of Peptidomimetic delta Opioid Receptor Antagonists Using the Message-Address Concept", J. Med. Chem., 33, 1714 (1990).
R. J. Roon et al., "Synthesis of Quisqualic Acid Analogues as Possible Selective Ligands at Quisqualic Acid Receptors", Soc. Neuroscience Abstracts, 18, 649 Abstract No. 277.16 (1992).
M. Sofuoglu et al., "Differential Antagonism of delta Opioid Agonists by Naltrindole and its Benzofuran Analog (NTB) in Mice: Evidence for delta Opioid Receptor Subtypes", J. Pharmacol. Exp. Ther., 257, 676 (1991).
N. Subasinghe et al., "Synthesis of Quisqualic Acid Analogues as Possible Selective Ligands at Quisqualic Acid Receptors", 23rd National Medicinal Chemistry Symposium, Buffalo N.Y., Abstract No. 12 (1992).
N. Subasinghe et al., "Quisqualic Acid Analogues: Snythesis of beta-Heterocyclic 2-Aminopropanoic Acid Derivatives and Their Activity at a Novel Quisqualate-Sensitized Site", J. Med. Chem., 35, 4602-2607 (1992).
J. R. Volpicelli et al., Opioids, Bulimia and Alcohol Abuse and Alcoholism, L. D. Reid, ed., Springer-Verlat at pp. 195-214 (1990).
S. Ward, "Improved Assays for the Assessment of kappa and delta -Properties of Opioid Ligands", Eur. J. Pharmacol., 85, 163 (1982).
L. Werling et al., "Opioid binding to Rat and Guinea Pig Neural Membranes in the Presence of Physiological Cations at 37.degree. C.", J. Pharmacol. Exp. Ther., 233 722 (1985).

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Kappa opioid receptor antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kappa opioid receptor antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kappa opioid receptor antagonists will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2311170

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.